Compare GDV & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | SDGR |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | GDV | SDGR |
|---|---|---|
| Price | $27.09 | $18.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.57 |
| AVG Volume (30 Days) | 186.0K | ★ 776.3K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $18.04 | $15.99 |
| 52 Week High | $23.00 | $28.47 |
| Indicator | GDV | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 50.16 |
| Support Level | $26.90 | $17.53 |
| Resistance Level | $27.47 | $18.28 |
| Average True Range (ATR) | 0.31 | 0.66 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 64.04 | 66.25 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.